WO2022188729 - FUSED RING DERIVATIVES USEFUL AS KRAS G12D INHIBITORS
National phase entry:
Publication Number
WO/2022/188729
Publication Date
15.09.2022
International Application No.
PCT/CN2022/079476
International Filing Date
07.03.2022
Title **
[English]
FUSED RING DERIVATIVES USEFUL AS KRAS G12D INHIBITORS
[French]
DÉRIVÉS CYCLIQUES FUSIONNÉS UTILES EN TANT QU'INHIBITEURS DE KRAS G12D
Applicants **
JACOBIO PHARMACEUTICALS CO., LTD.
Inventors
HAN, Huifeng
GAO, Panliang
MA, Cunbo
WANG, Peng
LONG, Wei
ZHANG, Hao
ZHANG, Lei
LIU, Dan
Priority Data
PCT/CN2021/079457
07.03.2021
CN
PCT/CN2021/100923
18.06.2021
CN
PCT/CN2021/120980
27.09.2021
CN
PCT/CN2022/071298
11.01.2022
CN
PCT/CN2022/073228
21.01.2022
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2948 | |
| EPO | Filing, Examination, Granting | 23064 | |
| Japan | Filing, Examination, Granting | 2870 | |
| South Korea | Filing, Examination, Granting | 3726 | |
| USA | Filing, Examination, Granting | 8740 |
Total:
41,348
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The disclosure relates to a KRAS G12D inhibitors of formula (I) or formula (IV), a composition containing the inhibitor and the use thereof.[French]
L'invention concerne des inhibiteurs de KRAS G12D de formule (I) ou de formule (IV), une composition contenant l'inhibiteur et leur utilisation.